Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation
Open Access
- 10 February 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
Abstract
Transplantation is the gold-standard treatment for the failure of several solid organs, including the kidneys, liver, heart, lung and small bowel. The use of tailored immunosuppressive agents has improved graft and patient survival remarkably in early post-transplant stages, but long-term outcomes are frequently unsatisfactory due to the development of chronic graft rejection, which ultimately leads to transplant failure. Moreover, prolonged immunosuppression entails severe side effects that severely impact patient survival and quality of life. The achievement of tolerance, i.e., stable graft function without the need for immunosuppression, is considered the Holy Grail of the field of solid organ transplantation. However, spontaneous tolerance in solid allograft recipients is a rare and unpredictable event. Several strategies that include peri-transplant administration of non-hematopoietic immunomodulatory cells can safely and effectively induce tolerance in pre-clinical models of solid organ transplantation. Mesenchymal stromal cells (MSC), non-hematopoietic cells that can be obtained from several adult and fetal tissues, are among the most promising candidates. In this review, we will focus on current pre-clinical evidence of the immunomodulatory effect of MSC in solid organ transplantation, and discuss the available evidence of their safety and efficacy in clinical trials.Keywords
Funding Information
- Agenzia Italiana del Farmaco, Ministero della Salute
- European Commission
This publication has 143 references indexed in Scilit:
- Mesenchymal Stem Cells Isolated from Adipose and Other Tissues: Basic Biological Properties and Clinical ApplicationsStem Cells International, 2012
- Mesenchymal-Stem-Cell-Induced Immunoregulation Involves FAS-Ligand-/FAS-Mediated T Cell ApoptosisCell Stem Cell, 2012
- Mesenchymal stem cells impair in vivo T-cell priming by dendritic cellsProceedings of the National Academy of Sciences of the United States of America, 2011
- Adipose-Tissue-Derived and Wharton's Jelly–Derived Mesenchymal Stromal Cells Suppress Lymphocyte Responses by Secreting Leukemia Inhibitory FactorTissue Engineering, Part A, 2010
- Safety and Immunological Effects of Mesenchymal Stem Cell Transplantation in Patients With Multiple Sclerosis and Amyotrophic Lateral SclerosisArchives of Neurology, 2010
- Bone marrow stromal cells use TGF-β to suppress allergic responses in a mouse model of ragweed-induced asthmaProceedings of the National Academy of Sciences of the United States of America, 2010
- Cell contact, prostaglandin E2 and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25Highforkhead box P3+ regulatory T cellsClinical and Experimental Immunology, 2009
- Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2009
- Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 productionNature Medicine, 2008
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006